### Supplementary Table 4. Comparison of Resistance Isolates among Community-Acquired, Healthcare-Associated, and Nosocomial Culture-Positive Spontaneous Ascitic Infections

| Bacterial distribution | All (n=455) | Community-acquired (n=107) | Healthcare-associated (n=157) | Nosocomial (n=191) | p value |
|------------------------|------------|---------------------------|-------------------------------|-------------------|--------|
| *E. coli*, ESBL        | 61 (13.4)  | 12 (11.2)                 | 21 (13.4)                    | 28 (14.7)        | 0.704  |
| *K. pn*, ESBL          | 11 (2.4)   | 1 (0.9)                   | 6 (3.8)                      | 4 (2.1)          | 0.302  |
| ESBL (*E. coli*+*K. pn*) | 72 (15.8)  | 13 (12.1)                 | 27 (17.2)                    | 32 (16.8)        | 0.489  |
| *E. coli*, FQR         | 68 (14.9)  | 14 (13.1)                 | 23 (14.6)                    | 31 (16.2)        | 0.759  |
| *K. pn*, FQR           | 8 (1.8)    | 1 (0.9)                   | 5 (3.2)                      | 2 (1.0)          | 0.344  |
| FQR (*E. coli*+*K. pn*) | 76 (16.7)  | 15 (14.0)                 | 28 (17.8)                    | 33 (17.3)        | 0.689  |
| Carbapenem-resistant GNB | 13 (2.9)  | 0 (0)                     | 2 (1.3)                      | 11 (5.8)         | 0.005  |
| MDR/XDR GNB*           | 82 (18.0)  | 16 (15.0)                 | 29 (18.5)                    | 37 (19.4)        | 0.625  |
| MRSA                   | 5 (1.1)    | 2 (1.9)                   | 2 (1.3)                      | 1 (0.5)          | 0.538  |
| MRSCoN                 | 37 (8.1)   | 11 (10.3)                 | 7 (4.5)                      | 19 (9.9)         | 0.114  |
| PRSV                   | 11 (2.4)   | 5 (4.7)                   | 2 (1.3)                      | 4 (2.1)          | 0.254  |
| MDR GPB†               | 20 (4.4)   | 2 (1.9)                   | 6 (3.8)                      | 12 (6.3)         | 0.187  |

ESBL, extended-spectrum β-lactamase; FQR, fluoroquinolone-resistant; GNB, gram-negative bacteria; MRSA, methicillin-resistant *Staphylococcus aureus*; MRSCoN, methicillin resistant coagulase-negative *Staphylococcus*; PRSV, penicillin-resistant *Streptococcus viridans*; GPB, gram-positive bacteria; MDR, multi-drug resistant; XDR, extensively drug resistant.

Data are presented as number (%).

*MDR/XDR GNB including Enterobacteriaceae, *Pseudomonas aeruginosa*, *Acinetobacter* spp.*

†MDR GPB including *Enterococcus* spp. and *Staphylococcus aureus*.